Association between initial combination antiretroviral regimen (Lamivudine/Non-lamivudine) and time to attrition overall and stratified by calendar year of therapy initiation.

Note: HR = hazard ratio; 95% CI = 95% Confidence Interval; † Includes initial regimen (lamivudine/Non-lamivudine) and patients’ age, gender, marriage status, HIV exposure category, CD4 cell counts, hemoglobin level, clinical symptoms, area of residence, health care setting but excludes the year of starting therapy. ‡ Includes all factors plus the year of starting therapy.
*Includes all factors but stratifies by the year of starting therapy.
**Because lamivudine was only available after 2005 in China; therefore we did not make estimates during 2003–2004.